Literature DB >> 25002876

Parathyroid nuclear scan. A focused review on the technical and biological factors affecting its outcome.

Subramanian Kannan1, Mira Milas2, Donald Neumann3, Rikesh T Parikh2, Alan Siperstein2, Angelo Licata4.   

Abstract

OBJECTIVE: Technetium Parathyroid Scintigraphy (TS) is the most popular noninvasive localization procedure in patients with primary hyperparathyroidism (PHPT). Awareness of various factors involved in technetium uptake helps understand the outcome of TS.
METHODS: We utilize a case of changing TS scans in a patient to review the literature on the various biological and technical factors involved in technetium uptake by the abnormal parathyroid tissue. A 56 year female was diagnosed with PHPT and osteopenia. An initial scan using (99m)Tc-Tetrofosmin showed no definite areas of abnormal parathyroid tissue. Patient refused surgical exploration, was started on Bisphosponates and subsequently monitored. Five years later she suffered fracture of her right wrist. A repeat TS using (99m)Tc-Sestamibi revealed hypervascular parathyroid lesion in the right lower neck. She underwent successful removal of a right lower parathyroid adenoma.
RESULTS: Technical factors like the type of Tc isotope used, imaging techniques and biological factors like biochemical parameters (calcium, vitamin D levels), adenoma size, content of oxyphilic cells, vascularity can affect the outcome of the scan.
CONCLUSION: Clinicians should be aware of technical and biological factors that could result in negative scan in parathyroid nuclear scintigraphy.

Entities:  

Keywords:  parathyroid nuclear scintigraphy; primary hyperparathyroidism; technetium sestamibi; technetium tetrofosmin

Year:  2014        PMID: 25002876      PMCID: PMC4064437     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  24 in total

1.  Relationship of technetium Tc 99m sestamibi scans to histopathological features of hyperfunctioning parathyroid tissue.

Authors:  Nicholas Y Mehta; James M Ruda; Silloo Kapadia; Phillip J Boyer; Christopher S Hollenbeak; Brendan C Stack
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2005-06

2.  99Tcm sestamibi--a new agent for parathyroid imaging.

Authors:  A J Coakley; A G Kettle; C P Wells; M J O'Doherty; R E Collins
Journal:  Nucl Med Commun       Date:  1989-11       Impact factor: 1.690

3.  In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria.

Authors:  N Hetrakul; A C Civelek; C A Stagg; R Udelsman
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

4.  Parameters in the prediction of the sensitivity of parathyroid scanning.

Authors:  Alan Siegel; Michael Alvarado; Richard J Barth; Matthew Brady; Jill Lewis
Journal:  Clin Nucl Med       Date:  2006-11       Impact factor: 7.794

5.  Chasing "shadows": discovering the subtleties of sestamibi scans to facilitate minimally invasive parathyroidectomy.

Authors:  Vladimir K Neychev; Guennadi Kouniavsky; Zita Shiue; Don N Udall; Helina Somervell; Christopher B Umbricht; Martha A Zeiger
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

6.  Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy.

Authors:  Pinhas P Schachter; Nidal Issa; Mordechai Shimonov; Abraham Czerniak; Mordechai Lorberboym
Journal:  Arch Surg       Date:  2004-04

7.  Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study)

Authors:  R Taillefer; Y Boucher; C Potvin; R Lambert
Journal:  J Nucl Med       Date:  1992-10       Impact factor: 10.057

8.  Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases.

Authors:  Allan Siperstein; Eren Berber; German F Barbosa; Michael Tsinberg; Andrew B Greene; Jamie Mitchell; Mira Milas
Journal:  Ann Surg       Date:  2008-09       Impact factor: 12.969

9.  Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma.

Authors:  Mehmet Haciyanli; Geeta Lal; Eugene Morita; Quan-Yang Duh; Electron Kebebew; Orlo H Clark
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

10.  The positive effect of adenoma weight and oxyphil cell content on preoperative localization with 99mTc-sestamibi scanning for primary hyperparathyroidism.

Authors:  Yeşim Erbil; Yersu Kapran; Halim Işsever; Umut Barbaros; Işik Adalet; Ferhunde Dizdaroğlu; Alp Bozbora; Selçuk Ozarmağan; Serdar Tezelman
Journal:  Am J Surg       Date:  2008-01       Impact factor: 2.565

View more
  5 in total

1.  Scan-directed mini-incision focused parathyroidectomy: how accurate is accurate enough?

Authors:  I M Shapey; S Jabbar; Z Khan; J E Nicholson; R J Watson
Journal:  Ann R Coll Surg Engl       Date:  2017-02       Impact factor: 1.891

Review 2.  Diagnostic Value of Choline PET in the Preoperative Localization of Hyperfunctioning Parathyroid Gland(s): A Comprehensive Overview.

Authors:  Cristina Ferrari; Giulia Santo; Paolo Mammucci; Antonio Rosario Pisani; Angela Sardaro; Giuseppe Rubini
Journal:  Biomedicines       Date:  2021-02-25

3.  Personalized nuclear imaging protocol in cases with nodular goiter and parathyroid adenoma.

Authors:  W Jalloul; R Tibu; T M Ionescu; C R Stolniceanu; I Grierosu; A Tarca; L Ionescu; M C Ungureanu; D Ciobanu; V Ghizdovat; C Stefanescu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

4.  Does levothyroxine administration impact parathyroid localization?

Authors:  Rachell R Ayers; Kirby Tobin; Rebecca S Sippel; Courtney Balentine; Dawn Elfenbein; Herbert Chen; David F Schneider
Journal:  J Surg Res       Date:  2015-03-31       Impact factor: 2.192

Review 5.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.